Video Experimental Relacionado
Updated: Feb 22, 2026
04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
29.7K
Es ketamina: una posible terapia adyuvante para la depresión resistente al tratamiento
Annie Huang1, Jennifer L Fernandez Vasquez1, Catherine A Yeager1
1From the DD Eisenhower Army Medical Center Family Medicine Residency, Augusta, GA (AH, JLFV, CAY).
Journal of the American Board of Family Medicine : JABFM
|February 20, 2026
Resumen
Laaugmentation de la terapia para la depresión resistente al tratamiento con esketamina muestra tasas de remisión más altas que la quetiapina. La esketamina ofrece una opción más eficaz para pacientes con depresión de difícil tratamiento.
Área de la Ciencia:
- Psiquiatría
- Farmacología
Sus antecedentes:
- La depresión resistente al tratamiento (TRD) representa un desafío clínico importante.
- Las opciones terapéuticas actuales para la TRD tienen limitaciones en cuanto a eficacia y perfiles de efectos secundarios.
Objetivo del estudio:
- Comparar la eficacia de la augmentation con esketamina frente a la augmentation con quetiapina en pacientes con depresión resistente al tratamiento.
Principales métodos:
- Un estudio comparativo que evalúa las tasas de remisión de pacientes con TRD.
- Los pacientes recibieron esketamina o quetiapina como augmentation a su régimen de medicación existente.
Principales resultados:
- La augmentation con esketamina demostró tasas de remisión significativamente mayores en comparación con la quetiapina.
- Esto sugiere un resultado clínico superior para la esketamina en esta población de pacientes.
Conclusiones:
- La augmentation con esketamina es una estrategia más eficaz para lograr la remisión en la depresión resistente al tratamiento que la quetiapina.
- Estos hallazgos respaldan la consideración de la esketamina para pacientes con depresión refractaria.
Videos de Conceptos Relacionados
01:30Electroconvulsive Therapy
1.4K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.4K
01:23Antidepressant Drugs: MAOIs and Other Agents
991
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
991
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
674
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
674
01:24Parenteral Anesthetics: Overview
789
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
789
01:26Psychosis: Goals of Pharmacotherapy
620
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
620
01:20Antiepileptic Drugs: Potassium Channel Activators
829
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
829